Global R&D Pipeline
My Favorite
Hot Targets:
EGFR
Back
Total number of drugs
1276
Phase II and later clinical stages
9.3%
Involving companies
1289
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PX-070101 | PX-070101 | Growth factors | Nervous System Diseases Cardiovascular Diseases Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases | EGFR agonists | Praxis Pharmaceutical SA | Praxis Pharmaceutical SA | Approved | - | Colombia | 2015-07-01 | - | - | - | - | - | - | PX-070101 | - | - | detail > | |
| Dacomitinib | Dacomitinib | Small molecule drug | Neoplasms Respiratory Diseases | EGFR exon 19 deletion inhibitors EGFR exon 21 L858R mutation inhibitors HER4 antagonists | Pfizer Inc. | Pfizer Inc. Pfizer Europe MA EEIG Pfizer Pharmaceuticals Korea Ltd. PF Consumer Healthcare Canada ULC Pfizer Japan, Inc. | Approved | Approved | United States China European Union Japan Canada Iceland South Korea Liechtenstein Norway | 2018-09-27 | 2019-05-15 | Orphan Drug（United States） Priority Review（China） Special Review Project（China） | - | - | - | - | Dacomitinib | - | - | detail > | |
| Pyrotinib Maleate | Pyrotinib Maleate | Small molecule drug | Neoplasms Skin and Musculoskeletal Diseases Respiratory Diseases Digestive System Disorders | EGFR antagonists HER2 antagonists HER4 antagonists | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Jiangsu Hengrui Pharmaceuticals Co., Ltd. Dr. Reddy's Laboratories Ltd. | Approved | Approved | China | 2018-08-12 | 2018-08-12 | Breakthrough Therapy（China） Priority Review（China） Special Review Project（China） Conditional marketing approval（China） | - | - | - | - | Pyrotinib Maleate | - | - | detail > | |
| Neratinib maleate | Neratinib maleate | Small molecule drug | Neoplasms Skin and Musculoskeletal Diseases Nervous System Diseases Digestive System Disorders Respiratory Diseases Other Diseases Eye Diseases | EGFR antagonists HER2 antagonists HER4 antagonists | Pfizer Inc. | Celcuity, Inc. Puma Biotechnology, Inc. Pierre Fabre Médicament SAS Zhejiang Fukang Pharmaceutical Co., Ltd. Convalife (Shanghai) Co. Ltd. Pharmaceutical Biotechnology Qidong Co. Ltd. National Comprehensive Cancer Network, Inc. Bixink, Inc. Specialised Therapeutics Australia Pty Ltd. Knight Therapeutics, Inc. Pierre Fabre Pharma GmbH | Approved | Approved | United States China European Union Canada Australia Switzerland Iceland South Korea Liechtenstein Norway | 2017-07-17 | 2020-04-27 | Fast Track（United States） Orphan Drug（United States） | - | - | - | - | Neratinib maleate | - | - | detail > | |
| Brigatinib | Brigatinib | Small molecule drug | Neoplasms Respiratory Diseases Nervous System Diseases Congenital Disorders Otorhinolaryngologic Diseases Skin and Musculoskeletal Diseases Other Diseases Immune System Diseases Hemic and Lymphatic Diseases | ALK inhibitors EGFR antagonists FLT3 inhibitors IGF-1R antagonists ROS1 inhibitors | ARIAD Pharmaceuticals, Inc. | Takeda Pharmaceutical Co., Ltd. Takeda Pharma SA Takeda Pharmaceuticals Korea Co., Ltd. Takeda Pharma A/S ARIAD Pharmaceuticals, Inc. Takeda Pharmaceutical (China) Co. Ltd. Takeda Pharmaceuticals Australia Pty Ltd. Takeda Pharmaceuticals U.S.A., Inc. | Approved | Approved | United States China European Union Japan Australia Iceland South Korea Liechtenstein Norway | 2017-04-28 | 2022-03-22 | Accelerated Approval（United States） Breakthrough Therapy（United States） Orphan Drug（United States） | - | - | - | - | Brigatinib | - | - | detail > | |
| Necitumumab | Necitumumab | Monoclonal antibody | Neoplasms Respiratory Diseases | EGFR antagonists | Eli Lilly & Co. | Eli Lilly & Co. Nippon Kayaku Co., Ltd. Eli Lilly Canada, Inc. | Approved | - | United States Japan Canada | 2015-11-24 | - | Fast Track（United States） Orphan Drug（United States） | - | - | - | - | Necitumumab | - | - | detail > | |
| Osimertinib mesylate | Osimertinib mesylate | Small molecule drug | Neoplasms Respiratory Diseases Nervous System Diseases Digestive System Disorders Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases | EGFR T790M inhibitors EGFR exon 19 deletion inhibitors EGFR exon 21 L858R mutation inhibitors | AstraZeneca Pharmaceuticals Co. Ltd. | AstraZeneca Investment (China) Co. Ltd. AstraZeneca AB AstraZeneca PLC AstraZeneca Pharmaceuticals LP Eli Lilly & Co. Sichuan Baili Pharmaceuticals Co.,Ltd AstraZeneca Pharmaceuticals Co. Ltd. Daiichi Sankyo Co., Ltd. Genentech, Inc. AstraZeneca Pty Ltd. AstraZeneca Canada, Inc. | Approved | Approved | United States China European Union Japan Canada Australia Switzerland Iceland South Korea Liechtenstein Norway | 2015-11-13 | 2017-03-22 | Accelerated Approval（United States） Breakthrough Therapy（China） Breakthrough Therapy（United States） Fast Track（United States） Orphan Drug（United States） Priority Review（Australia） Priority Review（China） Priority Review（United States） Special Review Project（China） Accelerated assessment（European Union） | - | - | - | - | Osimertinib mesylate | - | - | detail > | |
| Icotinib Hydrochloride | Icotinib Hydrochloride | Small molecule drug | Neoplasms Respiratory Diseases | EGFR exon 21 L858R mutation inhibitors | Betta Pharmaceuticals Co., Ltd. | Betta Pharmaceuticals Co., Ltd. | Approved | Approved | China | 2011-06-07 | 2011-06-07 | Priority Review（China） Special Review Project（China） | - | - | - | - | Icotinib Hydrochloride | - | - | detail > | |
| Becotatug vedotin | Becotatug vedotin | Antibody drug conjugate (ADC) | Neoplasms Mouth and Tooth Diseases Otorhinolaryngologic Diseases Other Diseases Digestive System Disorders Respiratory Diseases Urogenital Diseases | EGFR antagonists Tubulin inhibitors | Shanghai Miracogen, Inc. | Lepu Biopharma Co., Ltd. Shanghai Miracogen, Inc. Lepu Medical Technology (Beijing) Co., Ltd. | Approved | Approved | China | 2025-10-28 | 2025-10-28 | Breakthrough Therapy（China） Breakthrough Therapy（United States） Fast Track（United States） Orphan Drug（United States） Priority Review（China） Conditional marketing approval（China） | Becotatug | Mc-Val-Cit-PABC-PNP | MMAE | 4 | Becotatug vedotin | IgG1 - nd | - | detail > | |
| Recombinant epidermal growth factor(Center For Genetic Engineering And Biotechnology) | Recombinant epidermal growth factor(Center For Genetic Engineering And Biotechnology) | Growth factors | Nervous System Diseases Cardiovascular Diseases Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases | EGFR modulators | Centro de Ingenieria Genetica y Biotecnologia | Discovery Therapeutics Caribe LLC Centro de Ingenieria Genetica y Biotecnologia Bio-Manguinhos | Approved | Phase 3 | Cuba | 2007-09-01 | - | - | - | - | - | - | Recombinant epidermal growth factor(Center For Genetic Engineering And Biotechnology) | - | - | detail > |
Total 1276 data
1
2
3
4
5
6
...
127
128
